Primitive Neuroectodermal Tumor (PNET) – Pipeline Review, H2 2011

Primitive Neuroectodermal Tumor (PNET) – Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Primitive Neuroectodermal Tumor (PNET) - Pipeline Review, H2 2011', provides an overview of the Primitive Neuroectodermal Tumor (PNET) therapeutic pipeline. This report provides information on the therapeutic development for Primitive Neuroectodermal Tumor (PNET), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Primitive Neuroectodermal Tumor (PNET). 'Primitive Neuroectodermal Tumor (PNET) - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

• A snapshot of the global therapeutic scenario for Primitive Neuroectodermal Tumor (PNET).
• A review of the Primitive Neuroectodermal Tumor (PNET) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
• Coverage of products based on various stages of development ranging from discovery till registration stages.
• A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
• Coverage of the Primitive Neuroectodermal Tumor (PNET) pipeline on the basis of route of administration and molecule type.
• Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
• Key discontinued pipeline projects.
• Latest news and deals relating to the products.

Reasons to buy

• Identify and understand important and diverse types of therapeutics under development for Primitive Neuroectodermal Tumor (PNET).
• Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
• Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
• Devise corrective measures for pipeline projects by understanding Primitive Neuroectodermal Tumor (PNET) pipeline depth and focus of Primitive Neuroectodermal Tumor (PNET) therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Primitive Neuroectodermal Tumor (PNET) Overview
Therapeutics Development
An Overview of Pipeline Products for Primitive Neuroectodermal Tumor (PNET)
Primitive Neuroectodermal Tumor (PNET) Therapeutics under Development by Companies
Primitive Neuroectodermal Tumor (PNET) Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Primitive Neuroectodermal Tumor (PNET) Therapeutics – Products under Development by Companies
Primitive Neuroectodermal Tumor (PNET) Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Primitive Neuroectodermal Tumor (PNET) Therapeutics Development
ImClone Systems Incorporated
PharmaMar, S.A.
Primitive Neuroectodermal Tumor (PNET) – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
IMC-A12 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Zalypsis - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Oxaliplatin - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Carboplatin + Etoposide + Thiotepa - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Carboplatin + Etoposide + Thiotepa - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Carboplatin + Cisplatin + Cyclophosphamide + Etoposide + Leucovorin + Methotrexate + Thiotepa + Vincristine - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Filgrastim + Cyclophosphamide + Doxorubicin hydrochloride + Etoposide + Ifosfamide + Vincristine sulfate + Radiation therapy - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Cyclophosphamide + Etoposide + Cisplatin + Vincristine + Thiotepa + Melphalan + Radiation Therapy + Stem Cell Transplantation - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
ABT-888 + Temozolomide - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Cisplatin + Etoposide - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
IMC-A12 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Irinotecan + Temozolomide - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Tipifarnib - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Temozolomide + Irinotecan + Bevacizumab - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Filgrastim + Carboplatin + Cisplatin + Cyclophosphamide + Isotretinoin + Vincristine Sulfate + Radiation Therapy - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Filgrastim + Carboplatin + Cisplatin + Cyclophosphamide + Vincristine Sulfate + Radiation therapy - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Filgrastim + Cisplatin + Cyclophosphamide + Isotretinoin + Vincristine Sulfate + Radiation therapy - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
TTRNA-xALT + TTRNA-DCs - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Primitive Neuroectodermal Tumor (PNET) Therapeutics – Drug Profile Updates
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products Under Development for Primitive Neuroectodermal Tumor (PNET), H2 2011
Products under Development for Primitive Neuroectodermal Tumor (PNET) – Comparative Analysis, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Comparative Analysis by Late Stage Development, H2 2011
Comparative Analysis by Mid Clinical Stage Development, H2 2011
Comparative Analysis by Early Clinical Stage Development, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
ImClone Systems Incorporated, H2 2011
PharmaMar, S.A., H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Primitive Neuroectodermal Tumor (PNET) Therapeutics – Drug Profile Updates

LIST OF FIGURES

Number of Products under Development for Primitive Neuroectodermal Tumor (PNET), H2 2011
Products under Development for Primitive Neuroectodermal Tumor (PNET) – Comparative Analysis, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Late Stage Products, H2 2011
Mid Clinical Stage Products, H2 2011
Early Clinical Stage Products, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products, H2 2011
Assessment by Route of Administration, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Assessment by Stage and Molecule Type, H2 2011 Skip to top